<DOC>
	<DOCNO>NCT02656563</DOCNO>
	<brief_summary>This multicentre , phase II , randomize , open label study evaluate efficacy safety monthly Radium 223 prolong treatment interval men localize prostate cancer receive intermittent androgen ablation therapy rise PSA post-radiation post-prostatectomy , high risk occult metastasis .</brief_summary>
	<brief_title>Radium 223 Following Intermittent ADT</brief_title>
	<detailed_description>Eligible subject randomize 1:1 ratio receive either ( 1 ) study medication , Radium 223 monthly six month ( 2 ) treatment ( usual care ) . All patient physical exam , PSA , testosterone clinical lab test conduct monthly . Group 1 receive monthly Radium 233 begin one month discontinue ADT , maximum 6 month treatment . Radium-223 give accordance Canadian product label Product Monograph 50kBq/kg . If PSA reach 5ng/ml 7 month discontinue ADT , patient discontinue Radium 223 resume ADT . Group 2 therapy PSA reach 5ng/ml , point resume ADT .</detailed_description>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>1 . Able read write ( health outcome questionnaires self administer ) , understand instruction relate study procedure give write informed consent . 2 . Age ≥ 45 ≤ 85 year . 3 . Histologically documented diagnosis ( include Gleason grade ) adenocarcinoma prostate . 4 . Subject receive external beam radiation , brachytherapy radical prostatectomy treatment localized prostate cancer , treat primary androgen deprivation . 5 . Subject complete intermittent androgen ablation therapy complete ADT . 6 . Patients treat brachytherapy must least 3 year post implant . 7 . Subject meet follow criterion : PSA &gt; 5.0 &lt; 100 ng/ml rise 2 successive occasion least one month apart prior ADT . PSA must &lt; 2.0 68 month ADT ( +/ 4 week ) . At month 8 ( within 4 week month 8 ) , follow documentation PSA &lt; 2.0 , patient enter . Patients must also two follow high risk criterion : Primary Gleason score &gt; 8 Baseline PSA &gt; 20 ng/ml ( pretreatment ) PSA recurrence &gt; 0.2 within 1 year ( post RP ) PSA DT prior ADT &lt; 6 month PSA &gt; 1.0 ng/ml 8 month ADT 8 . Adequate hematological , liver , renal function include : Absolute neutrophil count ( ANC ) ≥ 1.5 x109/L Platelet count ≥ 100 x109/L Hemoglobin ≥10.0 g/dL ( 100 g/L ; 6.2 mmol/L ) Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Albumin &gt; 25 g/L 9 . Eastern Cooperative Oncology Group Performance ( ECOG ) performance 0 1 ( Appendix 2 ) . 10 . Negative bone scan negative CT scan visceral ( extra nodal ) mets within 12 month study entry . Bone scan CT may perform initiation ADT . If lymphadenopathy present , must &lt; 3 cm shortest diameter . 11 . Able swallow retain oral medication . 12 . Able willing participate full study . 13 . Willingness use condom sexually active . 1 . Previous treatment prostate cancer follow : Chemotherapy Hormonal therapy ( e.g . megestrol , medroxyprogesterone , cyproterone , DES ) within previous year . ( Note : Patients first cycle intermittent androgen deprivation therapy within 8 month initiate treatment eligible ) . Glucocorticoids ( except inhale topical ) within previous 3 month . Ketoconazole 2 . Concurrent previous use within 3 month follow medication : Finasteride Dutasteride Any investigational 5αreductase inhibitor Anabolic steroid Medications antiandrogenic property cimetidine . 3 . Patients may receive investigational agent within 30 day prior first dose study drug anytime study period . 4 . Subject currently evidence distant metastases bone scan , visceral metastasis CT scan . Patients bulky LN mets . ( &gt; 3 cm shortest diameter ) . ( Note : Adenopathy &lt; 3 cm shortest diameter exclusion criterion ) . 5 . Subject receive adjuvant neoadjuvant androgen ablation within previous 12 month . 6 . Any unstable serious coexist medical condition ( ) include limit uncontrolled diabetes , peptic ulcer disease , Crohn 's disease ulcerative colitis . 7 . Abnormal liver function test ( alkaline phosphatase [ ALP ] , alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) &gt; 2.5 time upper limit normal ( ULN ) bilirubin &gt; 1.5 time ULN ) 8 . Previous malignancy ( include curatively treat basal squamous cell carcinoma skin within previous 2 year Ta bladder cancer negative surveillance cystoscopy within past year ) . 9 . History current evidence drug alcohol abuse within past 12 month . 10 . History illness , opinion investigator , might confound result study pose additional risk subject . This include : Imminent spinal cord compression base clinical finding and/or magnetic resonance imaging ( MRI ) . Patients history spinal cord compression completely recover . Any infection ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 Grade 2 Cardiac Failure New York Heart Association ( NYHA ) Class III IV Bone marrow dysplasia Fecal incontinence 11 . Prior hemibody external radiotherapy , systemic therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 , radium223 dichloride ) .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>